Theravance Biopharma (TBPH) Projected to Post Quarterly Earnings on Wednesday

Theravance Biopharma (NASDAQ:TBPH) is projected to issue its quarterly earnings data after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $29.90 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Theravance Biopharma Trading Down 3.6 %

Shares of TBPH opened at $9.31 on Monday. Theravance Biopharma has a 12 month low of $7.44 and a 12 month high of $10.90. The stock’s 50 day moving average is $9.40 and its two-hundred day moving average is $8.90. The firm has a market cap of $457.81 million, a P/E ratio of -9.22 and a beta of 0.21.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.90% of the stock is owned by corporate insiders.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.